Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$11.79 USD

11.79
4,354,860

+2.59 (28.15%)

Updated Nov 7, 2024 01:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Seattle Genetics' Padcev Study Aids Urothelial Cancer Survival

by Zacks Equity Research

Seattle Genetics' (SGEN) phase III EV-301 study on Padcev meets the main goal of overall survival compared to chemotherapy in patients previously treated for locally advanced/metastatic urothelial cancer.

Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (EBS) Outperforming Other Medical Stocks This Year?

ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA

by Zacks Equity Research

The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.

Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers

by Zacks Equity Research

Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.

Merus (MRUS) Looks Good: Stock Adds 7% in Session

by Zacks Equity Research

Merus (MRUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Apellis Submits Pegcetacoplan Applications to FDA and EMA

by Zacks Equity Research

Apellis (APLS) submits an NDA to the FDA and an MAA to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.

IGM Biosciences (IGMS) Catches Eye: Stock Jumps 8.7%

by Zacks Equity Research

IGM Biosciences (IGMS) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Vaxart Gets FDA Nod for Phase I Study on Coronavirus Vaccine

by Zacks Equity Research

Vaxart's (VXRT) investigational new drug application for oral coronavirus vaccine candidate gets a clearance from the FDA. The company will begin a phase I study later this month.

Seattle Genetics Up on Two New Oncology Deals With Merck

by Zacks Equity Research

Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.

Vertex Eyes Label Expansion of Triple Combo CF Drug in Europe

by Zacks Equity Research

Vertex's (VRTX) label expansion application Kaftrio in combination with Kalydeco gets accepted for review by the European Medicines Agency.

Novartis' Eye Drug's Safety Label Update Approved by EMA

by Zacks Equity Research

Novartis' (NVS) eye drug Beovu's safety label update receives approval from the Committee for Medicinal Products for Human Use.

Mallinckrodt Gets CRL From FDA for Terlipressin, Shares Fall

by Zacks Equity Research

Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.

Galapagos (GLPG) Surges: Stock Moves 8.8% Higher

by Zacks Equity Research

Galapagos (GLPG) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Immunomedics to be Acquired by Gilead for About 21 Billion

by Zacks Equity Research

Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.

Atara (ATRA) Looks Good: Stock Adds 5.1% in Session

by Zacks Equity Research

Atara (ATRA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Emergent Biosolutions (EBS) closed at $98.08, marking a -0.93% move from the previous day.

Bayer Collaborates With Recursion for Fibrotic Diseases

by Zacks Equity Research

Bayer (BAYRY) inks deal with Recursion Pharmaceuticals for the treatment of fibrotic diseases.

    Exelixis Inks a Couple of Deals to Develop Novel ADCs for Cancer

    by Zacks Equity Research

    Exelixis (EXEL) signs a collaboration agreement with private biotech NBE-Therapeutics for developing novel antibody-drug conjugates (ADCS) to address cancer. It also inks a similar deal with Catalent.

    AVEO Acquires Full Global Rights to Ficlatuzumab From Biodesix

    by Zacks Equity Research

    AVEO reclaims complete rights to ficlatuzumab from Biodesix for an undisclosed sum. The candidate is being developed for several cancer indications.

    Catalyst (CPRX) Eyes Firdapse Label Expansion Amid Competition

    by Zacks Equity Research

    Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.

    Gilead Submits sBLA to FDA for CAR-T in Non-Hodgkin Lymphomas

    by Zacks Equity Research

    Gilead submits a supplemental Biologics License Application to the FDA for Yescarta for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.

    Gilead-HiFiBiO Ink Deal to Develop Antibodies Against Leukemia

    by Zacks Equity Research

    Gilead's (GILD) subsidiary, Kite, enters into a two-year research deal with HiFiBiOto develop antibodies against acute myeloid leukemia.

    Horizon Therapeutics' Stock Rises YTD on Approvals & Buyouts

    by Zacks Equity Research

    Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. It is making efforts to expand the label for its marketed drugs.

    Tenet Healthcare Offers Senior Unsecured Notes Worth $2.5B

    by Zacks Equity Research

    Tenet Healthcare (THC) exhibits prudence by issuing senior notes amid a low interest rate environment to procure funds.

    Intercept's (ICPT) Stock Rises After Layoff Announcement

    by Zacks Equity Research

    Intercept (ICPT) plans to lay off its workforce to save costs and streamline operations.